HULUWA(SH:605199)2021-04-28 16:00Financial Performance - Operating revenue for the quarter was CNY 308,485,460.64, representing a 19.23% increase year-over-year[6] - Net profit attributable to shareholders was CNY 23,699,852.49, up 39.45% compared to the same period last year[6] - Basic earnings per share increased to CNY 0.06, reflecting a 20% growth from CNY 0.05 in the same quarter last year[7] - The company reported a total profit of CNY 28,828,284.45 for Q1 2021, an increase of 31.4% from CNY 21,934,476.72 in Q1 2020[25] - Net profit for Q1 2021 reached CNY 23,683,806.11, representing a 39.5% increase from CNY 16,994,854.81 in Q1 2020[25] - The company’s total comprehensive income for Q1 2021 was CNY 23,683,806.11, compared to CNY 16,994,854.81 in Q1 2020[26] Cash Flow - The net cash flow from operating activities improved to -CNY 77,986,423.25, a 15.61% increase from -CNY 92,414,561.50 in the previous year[6] - In Q1 2021, the cash inflow from operating activities totaled ¥265,282,305.31, an increase from ¥236,968,976.77 in Q1 2020, representing an increase of approximately 12.5%[32] - The net cash outflow from operating activities was ¥77,986,423.25 in Q1 2021, an improvement compared to a net outflow of ¥92,414,561.50 in Q1 2020, indicating a reduction of about 15.6%[32] - The cash inflow from investment activities was ¥20,244,535.72 in Q1 2021, significantly lower than ¥140,492,901.51 in Q1 2020, reflecting a decrease of approximately 85.6%[33] - The net cash outflow from investment activities was ¥42,071,436.45 in Q1 2021, compared to a net outflow of ¥76,125,340.05 in Q1 2020, showing an improvement of about 44.8%[33] - The cash inflow from financing activities reached ¥165,983,500.00 in Q1 2021, up from ¥90,000,000.00 in Q1 2020, marking an increase of approximately 84.4%[33] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 1,525,004,570, a 0.25% increase from the previous year[6] - The company's total current assets as of March 31, 2021, amounted to RMB 276,514,702.79, a decrease from RMB 345,877,444.02 as of December 31, 2020[17] - Total current assets amounted to $933.16 million, a decrease from $959.64 million in the previous period, reflecting a decline of approximately 2.6%[18] - Total non-current assets increased to $591.84 million from $561.52 million, representing an increase of about 5.4%[18] - Total liabilities decreased to $579.94 million from $604.68 million, a reduction of approximately 4.1%[19] - Long-term borrowings increased to $110.65 million from $52.05 million, representing a substantial increase of approximately 112.5%[19] Shareholder Information - The total number of shareholders reached 33,337 at the end of the reporting period[10] - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., holds 41.76% of the shares, totaling 167,079,000 shares[11] Research and Development - Research and development expenses rose by 46.51% to RMB 13,690,147.15, indicating increased investment in drug development[14] - Research and development expenses increased to CNY 13,690,147.15 in Q1 2021, up 46.5% from CNY 9,344,219.90 in Q1 2020[24] Other Financial Metrics - The company reported a weighted average return on net assets of 2.55%, a decrease of 0.05 percentage points from the previous year[7] - The company received government subsidies amounting to RMB 4,118,315.28, a 215.09% increase compared to the previous year[15] - Unappropriated profits rose to $266.77 million from $244.52 million, an increase of about 9.1%[23] - The company experienced a credit impairment loss of CNY -2,440,548.31 in Q1 2021, compared to a loss of CNY -2,471,185.11 in Q1 2020[25] - Other income for Q1 2021 was CNY 4,118,315.28, significantly higher than CNY 1,307,040.45 in Q1 2020[24]